PubRank

Kasper Rossing

Author PubWeight™ 31.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003 3.95
2 Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003 3.12
3 Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007 2.84
4 Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002 2.41
5 Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. Eur J Heart Fail 2014 1.99
6 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010 1.90
7 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008 1.57
8 Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009 1.56
9 Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int 2005 1.52
10 Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005 1.40
11 Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 2006 1.37
12 Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010 1.12
13 Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One 2010 0.89
14 The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scand J Clin Lab Invest 2012 0.85
15 Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004 0.84
16 Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004 0.81
17 Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol 2013 0.81
18 Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J Renin Angiotensin Aldosterone Syst 2012 0.80
19 Serial measurements of high-sensitivity cardiac troponin T after exercise stress test in stable coronary artery disease. Biomarkers 2013 0.80
20 Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids 2011 0.80
21 Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure. Circ Heart Fail 2013 0.79